Ultimovacs Rebounds on New Universal Cancer Vaccine Data for Mesothelioma

After failing its primary endpoint of progression-free survival, new data shows UV1 plus Bristol Myers Squibb’s Opdivo and Yervoy reduces risk of death by 27% over the checkpoint inhibitors alone.

Related Keywords

Norway ,Spain ,Madrid ,Norwegian ,Bristol Myers Squibb Opdivo , ,Bristol Myers Squibb ,Orphan Drug Designation ,Fast Track Designation ,Resume ,Careers ,Ltimovacs Rebounds On New Universal Cancer Vaccine Data For Mesothelioma ,Iospace ,Advice ,